The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary analysis of a phase I study of SNK01 (Autologous Non-genetically Modified Natural Killer Cells With Enhanced Cytotoxicity) monotherapy in patients with advanced solid tumors.
 
Victoria S. Chua-Alcala
No Relationships to Disclose
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Erlinda Maria Gordon
Stock and Other Ownership Interests - Counterpoint Biomedica; Delta Next-Gene
Speakers' Bureau - AADi
Research Funding - Bristol Mers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of patents on targeting pharmaceutical agents to injured tissues
 
Ted T. Kim
No Relationships to Disclose
 
Simranjit Sekhon
No Relationships to Disclose
 
William Feske
No Relationships to Disclose
 
Lucia Hui
Employment - NKGen Biotech
Stock and Other Ownership Interests - NKGen Biotech
 
Brenda L. Gibson
Employment - NKGen Biotech
 
Paul Y Chang
Employment - DNAtrix; NKGen Biotech
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene; Cymabay Therapeutics; Gilead Sciences; Halozyme; Pfizer
 
Debra Robinson
Employment - Maverick Therapeutics; NKGen Biotech; Takeda
Leadership - Maverick Therapeutics
Stock and Other Ownership Interests - Amgen
 
Paul Y. Song
Employment - FuseBio Therapeutics; NKGen Biotech
Leadership - NKGen Biotech
Stock and Other Ownership Interests - FuseBio Therapeutics; NKGen Biotech
Consulting or Advisory Role - NKGen Biotech